Introducing patient-centric SARS-CoV-2 serology testing with Trajan Scientific and Medical and Synexa Life Sciences

Introducing patient-centric SARS-CoV-2 serology testing with Trajan Scientific and Medical and Synexa Life Sciences

February 17, 2021

In response to the COVID-19 pandemic, the biopharmaceutical industry has leapt into action to better understand the disease and develop suitable vaccines and therapies. Trajan Scientific and Medical and Synexa Life Sciences have developed and validated an innovative, market-leading SARS-CoV-2 serology assay, available for high-throughput clinical research applications, using Trajan's advanced precision microsampling technology to expedite therapy and vaccine development as well as large-scale screening, sero-surveillance and post-market surveillance initiatives.

With hemaPEN’s® innovative, easy-to-use design and microsampling technology, large scale screening and sero-surveillance studies post-vaccine roll out can be conducted safely and efficiently, while maintaining social distancing protocols and maintaining patient-centricity, comfort and convenience.

Combining this technology with Synexa’s innovative, market-leading SARS-CoV-2 serology assay - a versatile technology capable of detecting IgG, IgM, IgA and nAb antibody response, as well as their semi-quantification without the need for titration - has yielded a highly competitive and flexible assay, suitable across a wide range of applications.

Through this collaboration, Trajan and Synexa have developed a powerful platform to enable vaccine programs with more convenience and comfort for the patient, while retaining high quality data for understanding the safety and efficacy of vaccines.

If you would like more information about our product and service offering to assist and support your vaccine program, please contact us.

Download
Brochure - SARS-CoV-2 serology testing

Related news
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC's Analyst

More information
www.hemapen.com

Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1908 568 844
media@trajanscimed.com




Also in News

Baker Institute research leads to simple tests for heart and diabetes disease
Baker Institute research leads to simple tests for heart and diabetes disease

January 13, 2023

Read More

Trajan Scientific and Medical to license the Baker Institute’s lipidomic analysis methodology and metabolic risk scores algorithms.
Trajan Scientific and Medical to license the Baker Institute’s lipidomic analysis methodology and metabolic risk scores algorithms.

October 10, 2022

Trajan Scientific and Medical, and the Baker Heart and Diabetes Institute, have reached an in-principle understanding for Trajan to license the Baker Institute’s lipidomic analysis methodology and metabolic risk scores algorithms.

Read More

Fully automated MOSH/MOAH workflow with saponification is setting new standards
Fully automated MOSH/MOAH workflow with saponification is setting new standards

September 29, 2022

Since 2010, Axel Semrau, now part of the Trajan family, has enabled the automated determination of MOSH/MOAH in food, feed, beverages, and packaging. By maintaining close contact with users, the CHRONECT Workstation MOSH/MOAH has been continuously enhanced. In this way, a unique system has been created step by step and always at the cutting edge of technology. Our most recent advancement is the automation of the entire sample preparation with saponification and improved epoxidation, which opens up unprecedented possibilities.

Read More